Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors

US9567579B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9567579-B2
Application numberUS-201113014597-A
CountryUS
Kind codeB2
Filing dateJan 26, 2011
Priority dateMay 23, 2003
Publication dateFeb 14, 2017
Grant dateFeb 14, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention includes composition and methods for making and using a combinatorial library to identify modified thioaptamers that bind to, and affect the immune response of a host animal, transcription factors such as IL-6, NF-κB, AP-1 and the like. Composition and methods are also provided for the treatment of viral infections, as well as, vaccines and vaccine adjuvants are provided that modify host immune responses.

First claim

Opening claim text (preview).

What is claimed is: 1. A system for identifying one or more proteins that interact with a specific oligonucleotide on a bead comprising: an oligonucleotide-bead library for binding one or more proteins, wherein each bead of the oligonucleotide-bead library comprises more than one copy of a unique oligonucleotide having a unique sequence, wherein the unique oligonucleotides are attached to the beads by a hexaethyleneglycol linker, and wherein the oligonucleotides attached to the bead are not released during phosphoroamidite deprotection; and a bead separator wherein the one or more beads of the bead library to which protein has bound are separated by the bead separator. 2. The system of claim 1 , further comprising a nucleic acid sequencer to determine the sequence of the oligonucleotide. 3. The system of claim 1 , wherein the sequence of the oligonucleotides on the one or more beads that bind to known proteins is determined. 4. The system of claim 1 , wherein the one or more proteins bound to the oligonucleotide are extracted, separated and identified by liquid chromatography, mass spectrometry, or liquid chromatography and time of flight (TOF) mass spectrometry (MS) MALDI-TOF. 5. The system of claim 1 , further comprising a mass spectrometer to identify the proteins that have bound to the one or more oligonucleotide-beads. 6. The system of claim 1 , wherein the oligonucleotide is defined further as comprising an at least partially thio-modified oligonucleotide. 7. The system of claim 1 , wherein the one or more proteins is further defined as being a protein extracted from a cell. 8. The system of claim 1 , wherein the one or more proteins is further defined as being a protein extracted from a virally infected cell. 9. The system of claim 1 , wherein the one or more proteins is further defined as being a protein extracted from a diseased cell. 10. The system of claim 1 , wherein the bead library is substantially protein-free. 11. The system of claim 1 , wherein the bead library comprises an [S]-oligonucleotide or an [S 2 ]-oligonucleotide combinatorial bead library. 12. The system of claim 1 , wherein the oligonucleotides of the bead library are single stranded. 13. The system of claim 1 , wherein the oligonucleotides of the bead library comprises RNA. 14. The system of claim 1 , wherein the bead library comprises sequence motifs for high affinity with cellular proteins selected from the group consisting essentially of proteins that are members of the AP-1, RBP-Jκ, NF-κB, NF IL-6 , CREB and GRE protein families, and combinations thereof.

Assignees

Inventors

Classifications

  • SELEX · CPC title

  • Isolating an individual clone by screening libraries · CPC title

  • Sequencing of polypeptides · CPC title

  • Methods of protein analysis involving mass spectrometry · CPC title

  • Methods of protein analysis involving laser desorption ionisation mass spectrometry · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9567579B2 cover?
The present invention includes composition and methods for making and using a combinatorial library to identify modified thioaptamers that bind to, and affect the immune response of a host animal, transcription factors such as IL-6, NF-κB, AP-1 and the like. Composition and methods are also provided for the treatment of viral infections, as well as, vaccines and vaccine adjuvants are provided t…
Who is the assignee on this patent?
Gorenstein David G, Luxon Bruce A, Leary James, and 2 more
What technology area does this patent fall under?
Primary CPC classification C12N15/1048. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).